HRP20150587T1 - Postupak konjugiranja bakterijskog antigena s proteinskim nosaäśem - Google Patents
Postupak konjugiranja bakterijskog antigena s proteinskim nosaäśem Download PDFInfo
- Publication number
- HRP20150587T1 HRP20150587T1 HRP20150587TT HRP20150587T HRP20150587T1 HR P20150587 T1 HRP20150587 T1 HR P20150587T1 HR P20150587T T HRP20150587T T HR P20150587TT HR P20150587 T HRP20150587 T HR P20150587T HR P20150587 T1 HRP20150587 T1 HR P20150587T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- activated
- order
- protein carrier
- saccharide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 41
- 102000036639 antigens Human genes 0.000 title claims 41
- 108091007433 antigens Proteins 0.000 title claims 41
- 238000000034 method Methods 0.000 title claims 16
- 230000001580 bacterial effect Effects 0.000 title claims 7
- 230000021615 conjugation Effects 0.000 title claims 3
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108010078791 Carrier Proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 150000001720 carbohydrates Chemical class 0.000 claims 10
- 238000006243 chemical reaction Methods 0.000 claims 8
- 125000000879 imine group Chemical group 0.000 claims 8
- 239000002775 capsule Substances 0.000 claims 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 6
- 239000003638 chemical reducing agent Substances 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- 241000606768 Haemophilus influenzae Species 0.000 claims 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 3
- 229960000814 tetanus toxoid Drugs 0.000 claims 3
- 241000194032 Enterococcus faecalis Species 0.000 claims 2
- 241000194031 Enterococcus faecium Species 0.000 claims 2
- 241000588650 Neisseria meningitidis Species 0.000 claims 2
- 241000607142 Salmonella Species 0.000 claims 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 101710183389 Pneumolysin Proteins 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- -1 cyanoborohydride residue Chemical group 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (15)
1. Postupak konjugiranja antigena, naznačen time što se sastoji u koracima
a) aktiviranja antigena kako bi se dobio aktivirani antigen;
b) reakcije aktiviranog antigena s proteinskim nosačem kako bi se dobila iminska skupina koja povezuje aktivirani antigen s proteinskim nosačem; i
c) reduciranja iminske skupine reducensom koji sadrži triacetoksiborohidridni ostatak kako bi se dobio konjugirani antigen;
ili
a) aktiviranja antigena kako bi se dobio aktivirani antigen;
b’) reakcije aktiviranog antigena sa spojnicom kako bi se dobila iminska skupina koja povezuje aktivirani antigen na spojnicu;
c’) reduciranja iminske skupine reducensom koji sadrži triacetoksiborohidridni ostatak kako bi se dobio konjugat antigen-spojnica; i
d) reakcije kompleksa antigen-spojnica s proteinskim nosačem kako bi se dobio konjugirani antigen;
gdje antigen potječe iz bakterija Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Salmonella Vi ili Staphylococcus epidermidis, gdje je antigen saharid iz bakterijske kapsule, te gdje se korak a) sastoji u reakciji antigena s perjodatom.
2. Postupak konjugiranja antigena, naznačen time što se sastoji u koracima
a) aktiviranja antigena kako bi se dobio aktivirani antigen;
a’) liofiliziranja aktiviranog antigena i proteinskog nosača, uz naknadno rekonstituiranje u DMSO-u ili DMF-u;
b) reakcije aktiviranog antigena s proteinskim nosačem kako bi se dobila iminska skupina koja povezuje aktivirani antigen s proteinskim nosačem; i
c) reduciranja iminske skupine reducensom koji sadrži triacetoksiborohidridni ostatak kako bi se dobio konjugirani antigen;
ili
a) aktiviranja antigena kako bi se dobio aktivirani antigen;
a’) liofiliziranja aktiviranog antigena i spojnice, uz naknadno rekonstituiranje u DMSO-u ili DMF-u;
b’) reakcije aktiviranog antigena sa spojnicom kako bi se dobila iminska skupina koja povezuje aktivirani antigen s proteinskim nosačem; i
c’) reduciranja iminske skupine reducensom koji sadrži triacetoksiborohidridni ostatak kako bi se dobio konjugat antigen-spojnica;
d) reakcije kompleksa antigen-spojnica s proteinskim nosačem kako bi se dobio konjugirani antigen, gdje je antigen saharid iz bakterijske kapsule, te gdje se korak a) sastoji u reakciji antigena s perjodatom.
3. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što reducens ne sadrži cijanoborohidridni ostatak.
4. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je antigen bakterijski saharid podrijetlom iz bakterija S. pneumoniae, H. influenzae, N. meningitidis, S. aureus, E. faecalis, E. faecium, Salmonella Vi ili S. epidermidis.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što je antigen saharid iz kapsule serotipa bakterije S. pneumoniae, kojeg se bira iz skupine koju čine 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F i 33F.
6. Postupak u skladu s patentnim zahtjevom 5, naznačen time što je saharid iz bakterijske kapsule saharid 23F iz kapsule bakterije S. pneumoniae.
7. Postupak u skladu s patentnim zahtjevom 5, naznačen time što je saharid iz bakterijske kapsule saharid 6B iz kapsule bakterije S. pneumoniae.
8. Postupak u skladu s patentnim zahtjevom 5, naznačen time što bakterijski saharid je polisaharid ili oligosaharid iz bakterije Haemophilus influenzae b (Hib).
9. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što proteinski nosač je protein, kojeg se bira iz skupine koju čine tetanusni toksoid (TT), fragment C od TT, difterijski toksoid, CRM197, pneumolizin, protein D, PhtD, PhtDE i N19.
10. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se antigen i proteinski nosač liofiliziraju nakon koraka a).
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što se antigen i proteinski nosač liofiliziraju u prisutnosti nereducirajućeg šećera.
12. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak a) sastoji u reakciji antigena s 0,0001-0,7 molarnih ekvivalenata perjodata.
13. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uključuje dodatni korak e) pročišćavanja konjugiranog antigena i/ili uključuje dodatni korak f), gdje se konjugirani antigen sterilno filtrira i/ili dodatni korak miješanja konjugiranog antigena s dodatnim antigenima.
14. Postupak u skladu s patentnim zahtjevom 13, naznačen time što dodatni antigeni sadrže najmanje 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 saharida iz bakterije S. pneumoniae, koje se bira iz skupine koju čine 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F i 33F.
15. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se konjugirani antigen može pomiješati s adjuvansom, gdje je adjuvans aluminijeva sol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1103836.1A GB201103836D0 (en) | 2011-03-07 | 2011-03-07 | Conjugation process |
EP12707745.1A EP2683408B1 (en) | 2011-03-07 | 2012-03-05 | Process for conjugation of bacterial antigen to a carrier protein |
PCT/EP2012/053715 WO2012119972A1 (en) | 2011-03-07 | 2012-03-05 | Conjugation process |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150587T1 true HRP20150587T1 (hr) | 2015-07-03 |
Family
ID=43923310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150587TT HRP20150587T1 (hr) | 2011-03-07 | 2015-06-02 | Postupak konjugiranja bakterijskog antigena s proteinskim nosaäśem |
Country Status (20)
Country | Link |
---|---|
US (1) | US10669318B2 (hr) |
EP (1) | EP2683408B1 (hr) |
JP (1) | JP5976017B2 (hr) |
KR (1) | KR20140145941A (hr) |
CN (1) | CN103402544A (hr) |
BR (1) | BR112013021780B1 (hr) |
CA (1) | CA2828787C (hr) |
CY (1) | CY1116363T1 (hr) |
DK (1) | DK2683408T3 (hr) |
ES (1) | ES2540904T3 (hr) |
GB (1) | GB201103836D0 (hr) |
HR (1) | HRP20150587T1 (hr) |
HU (1) | HUE024995T2 (hr) |
PL (1) | PL2683408T3 (hr) |
PT (1) | PT2683408E (hr) |
RS (1) | RS54063B1 (hr) |
RU (1) | RU2013144555A (hr) |
SI (1) | SI2683408T1 (hr) |
SM (1) | SMT201500146B (hr) |
WO (1) | WO2012119972A1 (hr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015052684A2 (en) * | 2013-10-11 | 2015-04-16 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
PT3096786T (pt) * | 2014-01-21 | 2021-08-24 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2015110941A2 (en) * | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CN105934251A (zh) * | 2014-01-21 | 2016-09-07 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
EA201700177A1 (ru) * | 2014-10-09 | 2017-07-31 | Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. | Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком |
SG10202005253TA (en) * | 2015-07-21 | 2020-07-29 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
MX2019002489A (es) | 2016-09-02 | 2019-10-21 | Sanofi Pasteur Inc | Vacuna contra neisseria meningitidis. |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
WO2018144438A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
AU2018225083B2 (en) * | 2017-02-24 | 2023-06-01 | Merck Sharp & Dohme Llc | Pneumococcal conjugate vaccine formulations |
CN117982633A (zh) | 2017-12-06 | 2024-05-07 | 默沙东有限责任公司 | 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法 |
SG11202106541WA (en) | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
EP4243863A2 (en) | 2020-11-10 | 2023-09-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CN113274489B (zh) * | 2021-04-30 | 2023-08-29 | 山东省药学科学院 | 一种预防真菌感染的几丁质寡糖疫苗及其制备方法 |
EP4346893A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
IL98715A0 (en) | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
DE69324487T2 (de) | 1992-05-06 | 1999-08-12 | Harvard College | Rezeptorbindende region des diphtherietoxius |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
ATE226831T1 (de) | 1993-05-18 | 2002-11-15 | Univ Ohio State Res Found | Impfstoff gegen mittelohrentzündung |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
EP0914178B1 (en) | 1996-06-18 | 2003-03-12 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
EP1770164B1 (en) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6340461B1 (en) * | 1996-12-17 | 2002-01-22 | David Stephen Terman | Superantigen based methods and compositions for treatment of diseases |
DK0957972T3 (da) | 1996-12-20 | 2003-07-21 | Alza Corp | Anordning og fremgangsmåde til at forøge transdermal middelflux |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
CA2292838A1 (en) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Lactoferrin receptor genes of moraxella |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
CN1285753A (zh) | 1997-12-02 | 2001-02-28 | 鲍德杰克特疫苗公司 | 透皮给药微粒疫苗组合物 |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
GB9812613D0 (en) | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
NZ509986A (en) | 1998-08-19 | 2003-10-31 | Baxter Healthcare S | Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines |
AU1819400A (en) | 1998-11-17 | 2000-06-05 | Schlumberger Technology Corporation | Transmitting information over a communication link |
WO2000037105A2 (en) | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
EP1035137A1 (en) | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
MY125202A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
US6319224B1 (en) | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
PT1962899E (pt) | 2005-12-22 | 2011-10-19 | Glaxosmithkline Biolog Sa | Vacina conjugada polissacarídica pneumocócica |
GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
-
2011
- 2011-03-07 GB GBGB1103836.1A patent/GB201103836D0/en not_active Ceased
-
2012
- 2012-03-05 ES ES12707745.1T patent/ES2540904T3/es active Active
- 2012-03-05 HU HUE12707745A patent/HUE024995T2/en unknown
- 2012-03-05 WO PCT/EP2012/053715 patent/WO2012119972A1/en active Application Filing
- 2012-03-05 PL PL12707745T patent/PL2683408T3/pl unknown
- 2012-03-05 RU RU2013144555/15A patent/RU2013144555A/ru not_active Application Discontinuation
- 2012-03-05 DK DK12707745.1T patent/DK2683408T3/da active
- 2012-03-05 JP JP2013557059A patent/JP5976017B2/ja active Active
- 2012-03-05 KR KR1020137026405A patent/KR20140145941A/ko not_active Application Discontinuation
- 2012-03-05 EP EP12707745.1A patent/EP2683408B1/en active Active
- 2012-03-05 SI SI201230227T patent/SI2683408T1/sl unknown
- 2012-03-05 US US14/002,411 patent/US10669318B2/en active Active
- 2012-03-05 BR BR112013021780-4A patent/BR112013021780B1/pt active IP Right Grant
- 2012-03-05 CN CN2012800114321A patent/CN103402544A/zh active Pending
- 2012-03-05 PT PT127077451T patent/PT2683408E/pt unknown
- 2012-03-05 CA CA2828787A patent/CA2828787C/en active Active
- 2012-03-05 RS RS20150414A patent/RS54063B1/en unknown
-
2015
- 2015-06-02 HR HRP20150587TT patent/HRP20150587T1/hr unknown
- 2015-06-05 CY CY20151100498T patent/CY1116363T1/el unknown
- 2015-06-24 SM SM201500146T patent/SMT201500146B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20130344103A1 (en) | 2013-12-26 |
SI2683408T1 (sl) | 2015-07-31 |
DK2683408T3 (da) | 2015-06-15 |
PL2683408T3 (pl) | 2015-09-30 |
BR112013021780A2 (pt) | 2020-07-28 |
HUE024995T2 (en) | 2016-01-28 |
CY1116363T1 (el) | 2017-02-08 |
CA2828787C (en) | 2016-05-03 |
US10669318B2 (en) | 2020-06-02 |
BR112013021780B1 (pt) | 2022-07-26 |
ES2540904T3 (es) | 2015-07-14 |
GB201103836D0 (en) | 2011-04-20 |
WO2012119972A1 (en) | 2012-09-13 |
EP2683408A1 (en) | 2014-01-15 |
CN103402544A (zh) | 2013-11-20 |
SMT201500146B (it) | 2015-09-07 |
PT2683408E (pt) | 2015-07-17 |
JP2014507451A (ja) | 2014-03-27 |
JP5976017B2 (ja) | 2016-08-23 |
CA2828787A1 (en) | 2012-09-13 |
KR20140145941A (ko) | 2014-12-24 |
EP2683408B1 (en) | 2015-04-15 |
RU2013144555A (ru) | 2015-04-20 |
RS54063B1 (en) | 2015-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150587T1 (hr) | Postupak konjugiranja bakterijskog antigena s proteinskim nosaäśem | |
JP7268125B2 (ja) | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 | |
HRP20211288T1 (hr) | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati | |
HRP20170457T1 (hr) | Postupak proizvodnje cjepiva | |
HRP20171161T1 (hr) | Postupak konjugiranja bakterijskih polisaharida s proteinskim nosačima | |
JP6335326B2 (ja) | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用 | |
US20210236646A1 (en) | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres | |
JP2023113922A (ja) | 肺炎球菌多糖体および免疫原性多糖体-キャリアタンパク質コンジュゲートでのその使用 | |
NZ596500A (en) | Pneumococcal polysaccharide conjugate vaccine | |
JP2023052619A (ja) | 肺炎球菌多糖体および免疫原性多糖体-キャリアタンパク質コンジュゲートでのその使用 | |
JP2021505589A5 (hr) | ||
SA519401027B1 (ar) | تركيب متقارن من عديد السكاريد للمكورة الرئوية متعددة التكافؤ - وبروتين | |
CN110225757A (zh) | 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法 | |
MX2022001241A (es) | Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos. | |
MX2020002558A (es) | Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora. | |
WO2009000825A3 (en) | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates | |
MX2009006705A (es) | Composicion conjugada polisacarido-proteina neumococica multivalente. | |
HRP20220573T1 (hr) | Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima | |
PH12019500238A1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
WO2015052684A3 (en) | Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process of preparation thereof | |
EA201990131A1 (ru) | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция |